Patterns of biologic and targeted-synthetic disease-modifying antirheumatic drug use in rheumatoid arthritis in Australia
Authors:
Open Access
- 30 January 2022
- journal article
- research article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 61 (10) , 3939-3951
Abstract
The aim of this study was to describe treatment patterns in RA, including the frequency and reasons for switching or stopping biologic and targeted synthetic DMARDs (b/tsDMARDs). The reasons for switching or stopping b/tsDMARDs were extracted from the Australian Rheumatology Association Database (ARAD) from 2003 to 2018 for RA participants. Switching patterns for each b/tsDMARD and time on first-, second- and third-line b/tsDMARDs were evaluated using Sankey diagrams and survival methods. A total of 2839 participants were included in the analysis. The first-line b/tsDMARDs were etanercept (n = 1414), adalimumab (n = 1024), infliximab (n = 155), golimumab (n = 98), abatacept (n = 66), certolizumab (n = 38), tocilizumab (n = 21) and tofacitinib (n = 23). Of those starting first-, second- and third-line biologic therapy, 24.0%, 31.8% and 24.4% switched to another b/tsDMARD within 12 months, respectively. Inefficacy or adverse effects were the most common reasons for stopping therapy, irrespective of line of treatment. Compared with first-line etanercept, participants were more likely to stop adalimumab [Hazard ratio (HR) 1.16, 95% CI: 1.04, 1.29] and infliximab (HR 1.77, 95% CI: 1.46, 2.16). No differences were seen for other b/tsDMARDs. For second-line therapies compared with etanercept, the risk of stopping was lower for tocilizumab (HR 0.41, 95% CI: 0.25, 0.70), rituximab (HR 0.51, 95% CI: 0.30, 0.85) and tofacitinib (HR 0.29, 95% CI: 0.15, 0.57). Participants taking rituximab, tocilizumab and tofacitinib were also less likely to stop third-line therapy in comparison with participants taking etanercept. Switching between b/tsDMARDs was common among ARAD participants with RA, most commonly due to inefficacy or adverse effects. Durability of exposure and reasons for switching varied between b/tsDMARDs.Keywords
Funding Information
- The Australian Rheumatology Association Database
- Australian Rheumatology Association
- Pfizer Australia
- Abbvie Pty Ltd
- Eli Lilly Australia Pty Ltd Sanofi Australia
- Celgene Australian & NZ, Bristol Myers Squibb Australia Pty Ltd
- Amgen Australia Pty Ltd
- AstraZeneca
- Australian National Health and Medical Research Council
- NHMRC (384330)
- Cabrini Health, Monash University, Royal North Shore Hospital
- Australian Rheumatology Association
This publication has 40 references indexed in Scilit:
- Treatment Patterns, Direct Cost of Biologics, and Direct Medical Costs for Rheumatoid Arthritis Patients: A Real-world Analysis of Nationwide Japanese Claims DataClinical Therapeutics, 2016
- Rates, factors, reasons, and economic impact associated with switching in rheumatoid arthritis patients newly initiated on biologic disease modifying anti-rheumatic drugs in an integrated healthcare systemJournal of Medical Economics, 2016
- Impact of Switching From an Initial Tumor Necrosis Factor Inhibitor on Health Care Resource Utilization and Costs Among Patients With Rheumatoid ArthritisClinical Therapeutics, 2015
- Comparison of Biologic Disease-Modifying Antirheumatic Drug Therapy Persistence Between Biologics Among Rheumatoid Arthritis Patients Switching from Another BiologicRheumatology and Therapy, 2014
- Switching of biologic disease modifying anti-rheumatic drugs in patients with rheumatoid arthritis in a real world settingJournal of Medical Economics, 2014
- Trends in the Use of Biologic Agents Among Rheumatoid Arthritis Patients Enrolled in the US Medicare ProgramArthritis Care & Research, 2013
- Patterns of biologic agent utilization among patients with rheumatoid arthritis: a retrospective cohort studyBMC Musculoskeletal Disorders, 2011
- Switching between anti-tumour necrosis factors: trying to get a handle on a complex issueAnnals of the Rheumatic Diseases, 2007
- Effect of treatment with biological agents for arthritis in Australia: the Australian Rheumatology Association DatabaseInternal Medicine Journal, 2007
- EQ-SD: a measure of health status from the EuroQol GroupAnnals of Medicine, 2001